Radiopharmaceuticals and Tracers

This channel includes news and new technology innovations for nuclear and molecular imaging agents, radiotracers and radiopharmaceuticals used in PET or SPECT imaging. This includes advances in myocardiac perfusion agents.

New Production Method Promises to End Medical Radioisotope Shortages
April 22, 2022 — A commonly used radioisotope, technetium-99m, used in medical diagnoses regularly suffers from shortages due to being produced at aging…
VIDEO: Advances in Radiopharmaceutical Therapy
Ana Kiess, M.D., Ph.D., assistant professor of radiation oncology and molecular radiation sciences, Johns Hopkins University…
Bracco Imaging Acquires Blue Earth Diagnostics
Bracco Imaging S.p.A. has signed a definitive agreement to acquire Blue Earth Diagnostics, a molecular imaging company based in Oxford, U.K. Subject to customary closing conditions, completion of the transaction is expected in the third quarter of this calendar year.
Chalk River Isotope Reactor Decommissioning Date Set
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Laboratories’ (CNL) Nuclear Research and Test Establishment Operating License for the Chalk River Laboratories (CRL) site.
FDA Clears Path for First Domestic Supply of Tc-99m Isotope
February 8, 2018 — The U.S. Food and Drug Administration (FDA) and the Nuclear Regulatory Commission (NRC) recently took steps to ensure a stable and secure supply of a critical radioactive imaging tracer used to detect potentially life-threatening diseases.

News | SNMMI

SNMMI elects Cathy Sue Cutler, PhD, FSNMMI, as Vice President-Elect at 2022 Annual Meeting

June 16, 2022 — Cathy Sue Cutler, PhD, FSNMMI, director of the medical isotope research and production program at ...

June 16, 2022

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced the creation of the Mars Shot Fund, an initiative to raise $100 million to help pay for research into nuclear medicine, molecular imaging, and therapy.

News | SNMMI

SNMMI Launches Mars Shot Fund for Nuclear Medicine Research

June 14, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced the creation of the Mars Shot ...

June 14, 2022

News | SNMMI

SNMMI elects Munir Ghesani, MD, FACNM, FACR, as President at 2022 Annual Meeting

June 14, 2022 — Munir Ghesani, MD, FACNM, FACR, chief of nuclear medicine and molecular imaging at Mount Sinai Health ...

June 14, 2022

Sponsored Content

Blog | Contrast Media Injectors

BLOG: Smart Injector Technology Delivers Effective and Efficient Patient Care

Technology advancements are changing consumers’ expectations, driving industries to adapt and evolve, and the healthcare ...

April 29, 2021

SpectronRx, a leading contract development and manufacturing organization (CDMO) for the life sciences industry that specializes in radiopharmaceuticals, today announced that it will showcase its new Actinium-225 production facility during this year’s annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting being held June 11-14 in Vancouver, British Columbia, Canada.

News | Radiopharmaceuticals and Tracers

SpectronRx to Showcase New Facility for the Global Supply of Actinium-225 at SNMMI 2022

June 13, 2022 — SpectronRx, a leading contract development and manufacturing organization (CDMO) for the life sciences ...

June 13, 2022

Curie Therapeutics will be provided with priority access to NorthStar’s high purity non-carrier added (n.c.a.) Ac-225, which will be used to advance its multimodal pipeline of precision radiopharmaceuticals to address broad unmet needs in treatment of patients with solid tumors

News | Radiopharmaceuticals and Tracers

NorthStar Medical Radioisotopes and Curie Therapeutics Announce Priority Access Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

June 8, 2022 — NorthStar Medical Radioisotopes, LLC (‘NorthStar’), a global innovator in the development, production and ...

June 08, 2022

The global nuclear medicine market size is expected to reach $24.4 billion by 2030, expanding at a CAGR of 13.0% from 2022 to 2030.

Feature | Nuclear Imaging

Global Nuclear Medicine Market Analysis Report

The "Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics (SPECT, PET)), Therapeutics ...

May 26, 2022

Oral presentation based on Late-breaking Abstract featured at American Urological Association’s 2022 Annual Meeting (AUA2022)

News | Radiopharmaceuticals and Tracers

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA

May 16, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

May 16, 2022

A schematic of the 99Mo/99mTc production system based on an electron linear accelerator and activated carbon-based 99mTc generator

News | Radiopharmaceuticals and Tracers

New Production Method Promises to End Medical Radioisotope Shortages

April 22, 2022 — A commonly used radioisotope, technetium-99m, used in medical diagnoses regularly suffers from ...

April 22, 2022

The MARIA research reactor (Poland) has added additional operating days, which has helped to reduce the loss of HFR production capacity.

News | Nuclear Imaging

Update on HFR Reactor Outage – Medical Isotope Supply Returning to Normal

February 18, 2022 — The Nuclear Medicine Europe (NMEu) Emergency Response Team held a call on February 14 on the ...

February 18, 2022

MURR staff work to produce lutetium-177 (Lu-177). Image courtesy of the University of Missouri

News | Nuclear Imaging

University of Missouri Research Reactor Helps Supply Critical Medical Isotopes During Global Disruption

February 11, 2022 — Due to a recent unexpected reactor shutdown in Europe, the University of Missouri Research Reactor ...

February 11, 2022

Videos | Radiopharmaceuticals and Tracers

VIDEO: Advances in Radiopharmaceutical Therapy

Ana Kiess, M.D., Ph.D., assistant professor of radiation oncology and molecular radiation sciences, Johns Hopkins ...

November 17, 2021

Bicameral legislation in U.S. House and Senate designed to address equity issues in patient access and affordability for innovative diagnostic radiopharmaceuticals

News | Radiopharmaceuticals and Tracers

Blue Earth Diagnostics Supports Timely Consideration and Passage of the FIND Act of 2021 by U.S. Congress

September 17, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

September 17, 2021

NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the signing of a supply agreement for the therapeutic medical radioisotope actinium-225 (Ac-225).

News | Radiopharmaceuticals and Tracers

NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

September 10, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

September 10, 2021

GE Healthcare also recently announced Xeleris V, a new virtualized, flexible AI-powered solution that provides clinicians secure access to data from anywhere – helping them make personalized care decisions and treatment recommendations that are at the heart of precision health.

News | Nuclear Imaging

GE Healthcare Advances Precision Health & Theranostics With New Products & Solutions

June 22, 2021 — At the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2021 summer conference, GE Healthcare ...

June 22, 2021

Master Supply Agreement encompasses clinical development and commercial supply for Clarity’s Cu-67-based candidates to treat neuroblastoma, breast and prostate cancers, among others

News | Radiopharmaceuticals and Tracers

NorthStar Medical Radioisotopes Enters U.S. Supply Agreement for Commercial Supply of Therapeutic Radioisotope Copper-67 (Cu-67)

June 22, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

June 22, 2021

Sponsored Content | Blog | Contrast Media Injectors

BLOG: Smart Injector Technology Delivers Effective and Efficient Patient Care

Technology advancements are changing consumers’ expectations, driving industries to adapt and evolve, and the healthcare ...

April 29, 2021

News | Radiopharmaceuticals and Tracers

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress

April 16, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

April 16, 2021

Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status

News | Radiopharmaceuticals and Tracers

Shine Medical Announces its Isotope Production Facility is Weathertight

March 26, 2021 — Shine Medical Technologies LLC announced that construction of the exterior structure of its first-of-a ...

March 26, 2021

Diagnostic imaging studies using Tc-99m inform healthcare decisions for approximately 30 million patients annually around the world

News | Nuclear Imaging

IBA and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Tc-99m

March 8, 2021 — IBA (Ion Beam Applications S.A., EURONEXT) and NorthStar Medical Radioisotopes, LLC, announced a ...

March 08, 2021

NMP to evaluate technology to create new class of PET radiopharmaceuticals

News | PET Imaging

Fuzionaire Radioisotope Technologies K.K. and Nihon Medi-Physics Enter Feasibility Study Agreement

January 29, 2021 — Fuzionaire Radioisotope Technologies K.K. (“FRIT”) announced that it has entered into a feasibility ...

January 29, 2021